Report Details:
15 Companies Covered
124 Pages
Growing Healthcare Demand and Technological Advancements to Propel Intravenous Solution Market to USD 33.92 Billion by 2035 – MRFR Report
Market Research Future (MRFR) has published a cooked research report on the “Global Intravenous Solution Market” containing analysis from 2018 to 2035. The Global Intravenous Solution Market is projected to grow from USD 16.13 billion in 2025 to USD 33.92 billion by 2035, registering a CAGR of 7.72% during the forecast period (2025–2035). As per MRFR analysis, the market was valued at USD 14.97 billion in 2024. Market growth is being driven by the rising incidence of chronic diseases, technological advancements in IV formulations, and growing demand for efficient hydration therapies and parenteral nutrition across healthcare settings worldwide.
MRFR recognizes the following companies as the key players in the Global Intravenous Solution Market: Baxter International Inc. (US), Fresenius SE & Co. KGaA (Germany), Braun Melsungen AG (Germany), ICU Medical Inc. (US), Pfizer Inc. (US), Grifols S.A. (Spain), and Terumo Medical Corporation (Japan).
Market Highlights
The Global Intravenous Solution Market is witnessing robust growth driven by increasing healthcare demands and advancements in IV therapy technology. The market, valued at USD 14.97 billion in 2024, is projected to expand to USD 33.92 billion by 2035 at a CAGR of 7.72% from 2025 to 2035. The surge in demand for intravenous therapy is attributed to the rising burden of chronic diseases, the aging population, and expanding access to modern healthcare services. Intravenous solutions have become essential in hospitals and home care settings due to their vital role in delivering medications, fluids, and nutrients directly into the bloodstream for rapid therapeutic effects.
Total parenteral nutrition continues to hold a dominant position in the market, accounting for around 62–66% share in 2021, reflecting its wide adoption among patients who cannot receive nutrients through oral or enteral routes. The growing number of patients with gastrointestinal conditions such as Crohn’s disease and ulcerative colitis has further elevated the use of intravenous nutrition therapy. At the same time, ongoing innovations — including smart IV pumps, automated compounding systems, and the development of PVC-free and non-latex IV bags — are enhancing the precision and safety of intravenous treatments.
Additionally, the emergence of home healthcare services is reshaping the industry as more patients prefer at-home treatment options. The shift to home care is anticipated to boost demand for flexible and easy-to-administer IV solutions, further strengthening market growth. The increasing awareness of IV therapy’s benefits — such as faster drug delivery and efficient hydration — is also fostering market expansion across both developed and developing regions.
Segment Analysis
The Global Intravenous Solution Market is segmented based on Nutrition Type, Bag Type, Nutritional Content, End User, and Region.
By Nutrition Type, the market is divided into Peripheral Parenteral Nutrition and Total Parenteral Nutrition. The Total Parenteral Nutrition (TPN) segment accounted for the largest share, approximately 62–66% of total revenue in 2021, due to its essential role in patients unable to obtain adequate nutrition through conventional methods. The aging population and increasing prevalence of gastrointestinal disorders continue to drive this segment’s dominance.
By Bag Type, the market includes Large Volume Bags (>250 ml) and Small Volume Bags (<250 ml). The Small Volume Bags (<250 ml) segment held the largest revenue share in 2021, supported by their widespread use in treating infectious diseases and meeting emergency infusion needs. The introduction of non-PVC and non-latex bag materials is improving safety and performance, supporting market adoption.
By Nutritional Content, the market covers Amino Acid Solutions, Carbohydrates, Vitamins & Minerals, Parenteral Lipid Emulsion, and Others. The Amino Acid Solution segment led the market in 2021 due to increasing approvals for enhanced formulations with reduced side effects and the growing use of amino-acid-based parenteral solutions for patients with nutrient deficiencies or hepatic diseases.
By End User, the market is categorized into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care. The Hospitals & Clinics segment held a significant share in 2021 owing to the rise in surgical procedures and metabolic disorders requiring IV therapy. Meanwhile, the growing number of ambulatory centers and home care settings is expected to broaden market reach by offering more accessible patient care solutions.
Regional Analysis
Regionally, the Global Intravenous Solution Market is studied across North America, Europe, Asia-Pacific, and the Rest of the World. North America held a dominant position in 2021, valued at USD 2.8 billion, and is projected to grow at a substantial CAGR over the forecast period. The region’s strong healthcare infrastructure, rising geriatric population, and high prevalence of chronic illnesses have been key factors supporting market growth. The U.S. and Canada remain major contributors due to increased demand for IV therapies in both emergency and elective care.
Europe represented the second-largest market for intravenous solutions, driven by an aging population, strong regulatory support, and technological advancement in IV formulations. The U.K. led the region, while France was the fastest-growing market, supported by favorable reimbursement frameworks and a robust hospital network.
The Asia-Pacific region is anticipated to record the fastest CAGR through 2035, fueled by increasing healthcare investments, expanding hospital infrastructure, and rising chronic disease prevalence in countries such as China, India, and Japan. High public and private expenditure in healthcare R&D and growing awareness of preventive care are accelerating regional market growth. Furthermore, the increasing collaboration between healthcare providers and research institutions is driving innovation and expanding access to cost-effective IV treatments across the region.
Key Findings of the Study
- The Global Intravenous Solution Market is projected to grow from USD 16.13 Billion in 2025 to USD 33.92 billion by 2035, at a CAGR of 7.72%.
- The market was valued at USD 14.97 billion in 2024.
- Total Parenteral Nutrition (TPN) accounted for 62–66% of the market share in 2021.
- Small Volume Bags (<250 ml) led by bag type segment.
- Amino Acid Solution is dominated by nutritional content.
- Hospitals & Clinics held the largest end-user share, while Home Care is emerging as a key growth area.
- North America led the global market with USD 2.8 billion in 2021.
- The Asia-Pacific region is expected to record the fastest growth through 2035.
- Rising prevalence of chronic diseases, growing home healthcare adoption, and advancements in IV formulations are driving overall market expansion.
Related Report
https://www.marketresearchfuture.com/reports/intravenous-solution-market-1235 \Top of Form
Bottom of Form